DOCS Stock Analysis — Doximity
Sector: Healthtech Software
AI Verdict
DOCS trades at 16.8x next year's earnings while analysts expect 28.0% EPS growth—cheap for the growth you're getting if its entrenched physician network keeps competitors at bay.
Competitive Moat
Doximity operates the largest professional network for U.S. physicians, giving it a data and network effect moat as doctors rely on its platform for secure communication and workflow tools. Its integration into daily medical practice makes switching costly for users and difficult for competitors to replicate.
Summary
Doximity's platform is sticky with U.S. doctors, anchoring it as the default digital workflow and communication hub in healthcare.
Where It Stands
DOCS trades at 16.8x forward earnings, well below the software sector median of 35x, while delivering 28.0% forward EPS growth and a trailing PEG of 0.77.
Key Metrics
- Trailing P/E: 21.5x
- Forward P/E: 16.8x
- PEG Ratio: 0.77
- Earnings Growth: +0.3%
- Revenue Growth: +0.2%
- 52-Week High: $76.51
- 52-Week Low: $20.55
Analyst Consensus
22 Buy · 8 Hold · 0 Sell (30 analysts)
Bull Case
With forward EPS expected to jump 28.0% and a forward P/E of just 16.8x, the stock is priced cheaply relative to its growth rate.
Bear Case
If P/E reverts to the sector median of 35x, upside is possible, but if growth slows and DOCS is re-rated down to a 14x financials median, shares could lose roughly 17%.
Catalyst to Watch
Watch for user engagement or platform expansion updates—any slowdown in physician adoption could challenge the moat and growth assumptions.